Multi-Parametric Cardiac Magnetic Resonance for Prediction of Heart Failure Death in Thalassemia Major

We assessed the prognostic value of multiparametric cardiovascular magnetic resonance (CMR) in predicting death from heart failure (HF) in thalassemia major (TM). We considered 1398 white TM patients (30.8 ± 8.9 years, 725 women) without a history of HF at baseline CMR, which was performed within the Myocardial Iron Overload in Thalassemia (MIOT) network. Iron overload was quantified by using the T2* technique, and biventricular function was determined with cine images. Late gadolinium enhancement (LGE) images were acquired to detect replacement myocardial fibrosis. During a mean follow-up of 4.83 ± 2.05 years, 49.1% of the patients changed the chelation regimen at least once; these patients were more likely to have significant myocardial iron overload (MIO) than patients who maintained the same regimen. Twelve (1.0%) patients died from HF. Significant MIO, ventricular dysfunction, ventricular dilation, and replacement myocardial fibrosis were identified as significant univariate prognosticators. Based on the presence of the four CMR predictors of HF death, patients were divided into three subgroups. Patients having all four markers had a significantly higher risk of dying for HF than patients without markers (hazard ratio (HR) = 89.93; 95%CI = 5.62–1439.46; p = 0.001) or with one to three CMR markers (HR = 12.69; 95%CI = 1.60–100.36; p = 0.016). Our findings promote the exploitation of the multiparametric potential of CMR, including LGE, for better risk stratification for TM patients.

[1]  H. Ardehali,et al.  The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease , 2022, Nature Reviews Cardiology.

[2]  Xiangyu Zhang,et al.  Iron in Cardiovascular Disease: Challenges and Potentials , 2021, Frontiers in Cardiovascular Medicine.

[3]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[4]  R. de Caterina,et al.  Myocardial iron overload by cardiovascular magnetic resonance native segmental T1 mapping: a sensitive approach that correlates with cardiac complications , 2021, Journal of Cardiovascular Magnetic Resonance.

[5]  V. Positano,et al.  National networking in rare diseases and reduction of cardiac burden in thalassemia major , 2021 .

[6]  OUP accepted manuscript , 2021, European Heart Journal.

[7]  V. Positano,et al.  Biventricular Reference Values by Body Surface Area, Age, and Gender in a Large Cohort of Well‐Treated Thalassemia Major Patients Without Heart Damage Using a Multiparametric CMR Approach , 2020, Journal of magnetic resonance imaging : JMRI.

[8]  M. Dweck,et al.  Myocardial fibrosis: why image, how to image and clinical implications , 2019, Heart.

[9]  V. Positano,et al.  MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine , 2018, British journal of haematology.

[10]  V. Positano,et al.  Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: a prospective multicentre study by a multi-parametric approach , 2018, European heart journal cardiovascular Imaging.

[11]  Aref Albakri Iron overload cardiomyopathy: A review of literature on clinical status and meta-analysis of diagnostic and clinical management using iron chelators , 2018 .

[12]  A. Maggio,et al.  The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major , 2017, British journal of haematology.

[13]  D. Pennell,et al.  Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging , 2017, Hematology.

[14]  V. Positano,et al.  Myocardial fibrosis by late gadolinium enhancement cardiac magnetic resonance and hepatitis C virus infection in thalassemia major patients , 2015, Journal of cardiovascular medicine.

[15]  V. Positano,et al.  Multiparametric Cardiac Magnetic Resonance Survey in Children With Thalassemia Major: A Multicenter Study , 2015, Circulation. Cardiovascular imaging.

[16]  V. Positano,et al.  Improvement of heart iron with preserved patterns of iron store by CMR-guided chelation therapy. , 2015, European heart journal cardiovascular Imaging.

[17]  V. Positano,et al.  Different patterns of myocardial iron distribution by whole-heart T2* magnetic resonance as risk markers for heart complications in thalassemia major. , 2014, International journal of cardiology.

[18]  Milton Packer,et al.  Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. , 2014, Journal of the American College of Cardiology.

[19]  M. Lombardi,et al.  Myocardial iron overload in thalassaemia major. How early to check? , 2014, British journal of haematology.

[20]  V. Positano,et al.  Cardiac complications and diabetes in thalassaemia major: a large historical multicentre study , 2013, British journal of haematology.

[21]  D. Pennell,et al.  Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. , 2013, Circulation.

[22]  H. Rienhoff,et al.  The use of appropriate calibration curves corrects for systematic differences in liver R2* values measured using different software packages , 2013, British journal of haematology.

[23]  V. Positano,et al.  Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy , 2013, Journal of Cardiovascular Magnetic Resonance.

[24]  D. Pennell,et al.  Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major , 2012, Haematologica.

[25]  M. R. Lamprecht,et al.  Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death , 2012, Cell.

[26]  V. Positano,et al.  Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging study , 2011, Haematologica.

[27]  Massimo Lombardi,et al.  Single region of interest versus multislice T2* MRI approach for the quantification of hepatic iron overload , 2011, Journal of magnetic resonance imaging : JMRI.

[28]  C. Jellis,et al.  Echocardiographic assessment of raised pulmonary vascular resistance: application to diagnosis and follow-up of pulmonary hypertension , 2010, Heart.

[29]  Dudley J Pennell,et al.  Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[30]  D. Weatherall Thalassemia as a global health problem: recent progress toward its control in the developing countries , 2010, Annals of the New York Academy of Sciences.

[31]  V. Positano,et al.  Preferential patterns of myocardial iron overload by multislice multiecho T*2 CMR in thalassemia major patients , 2010, Magnetic resonance in medicine.

[32]  Raffaella Origa,et al.  BETA THALASSEMIA , 2018, The Professional Medical Journal.

[33]  V. Positano,et al.  Safety of cardiovascular magnetic resonance gadolinium chelates contrast agents in patients with hemoglobinopathies , 2009, Haematologica.

[34]  Luigi Landini,et al.  Evaluation of a web-based network for reproducible T2* MRI assessment of iron overload in thalassemia , 2009, Int. J. Medical Informatics.

[35]  Massimo Midiri,et al.  Multicenter validation of the magnetic resonance t2* technique for segmental and global quantification of myocardial iron , 2009, Journal of magnetic resonance imaging : JMRI.

[36]  P. Moraitis,et al.  The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study , 2009, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[37]  V. Positano,et al.  Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major , 2009, Heart.

[38]  V. Positano,et al.  Influence of myocardial fibrosis and blood oxygenation on heart T2* values in thalassemia patients , 2009, Journal of magnetic resonance imaging : JMRI.

[39]  J. Wood Cardiac Complications in Thalassemia Major , 2009, Hemoglobin.

[40]  T. Coates,et al.  Longitudinal analysis of heart and liver iron in thalassemia major. , 2008, Blood.

[41]  Matthew W. Darlison,et al.  Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance , 2008, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[42]  S. Ha,et al.  Effect of deferasirox (ICL670) on arterial function in patients with beta‐thalassaemia major , 2008, British journal of haematology.

[43]  Massimo Midiri,et al.  Standardized T2* map of normal human heart in vivo to correct T2* segmental artefacts , 2007, NMR in biomedicine.

[44]  E. Gotsis,et al.  Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. , 2007, Haematologica.

[45]  V. Positano,et al.  Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload , 2006, Journal of magnetic resonance imaging : JMRI.

[46]  V. Positano,et al.  Evaluation of the efficacy of oral deferiprone in β‐thalassemia major by multislice multiecho T2* , 2006, European journal of haematology.

[47]  D N Firmin,et al.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.

[48]  J. Porter Practical management of iron overload , 2001, British journal of haematology.

[49]  C. McLaren,et al.  Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.

[50]  J. Clegg,et al.  Thalassemia — a global public health problem , 1996, Nature Medicine.

[51]  P. Toutouzas,et al.  Myocarditis in β-Thalassemia Major A Cause of Heart Failure , 1995 .

[52]  R. Adolph,et al.  Cardiovascular effects of anemia. , 1972, American heart journal.